How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,389 results for

Cerebrovascular Accident Risk in Women

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

ischemic heart disease, known coronary artery disease or known significant cardiac arrhythmias or severe congestive heart failure (New York Heart Association classes III or IV), recent cerebrovascular accidents, severe, progressive or uncontrolled neurological disease, and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol Women of childbearing potential who are sexually active and who do not agree to practiceone (...) Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2013 Clinical Trials

82. Individualized Prevention Strategy for High Risk Patients in Cardiovascular Disease: Prospective Cohort Study (Cardiovascular and Metabolic Disease Etiology Research Center

with microalbumin ration (AC ratio >= 30mg/g) anuric ESRD patients on dialysis the relatives of acute myocardial infarction patients under 55 years old (men)/ 65 years old (women) atherosclerotic cardiovascular disease (abdominal aorta diameter ≥3 cm or ankle-brachial index <0.9, or carotid plaque or carotid intima-media thickness ≥0.9 mm, or asymptomatic old cerebrovascular accident, or >30% stenosis in at least one major coronary artery) rheumatoid arthritis patients aged > 40 years on MTX and steroid therapy (...) Individualized Prevention Strategy for High Risk Patients in Cardiovascular Disease: Prospective Cohort Study (Cardiovascular and Metabolic Disease Etiology Research Center Individualized Prevention Strategy for High Risk Patients in Cardiovascular Disease: Prospective Cohort Study (Cardiovascular and Metabolic Disease Etiology Research Center - HIgh Risk Cohort) CMERC-HI - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2013 Clinical Trials

83. A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

(ECOG) performance status of 0-2. Subject has been evaluated by a local neurologist prior to study entry who has determined the subject has at least one risk factor for seizure including: past history of seizure due to any cause except a single febrile seizure in childhood. Patients with a history of seizures should not have had a seizure within 12 months of Screening and must have had no anticonvulsants for 12 months prior to Screening, history of cerebrovascular accident (CVA) or transient (...) A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2013 Clinical Trials

84. Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients

Posted : August 30, 2017 Sponsor: Stanford University Information provided by (Responsible Party): Greg Zaharchuk, Stanford University Study Details Study Description Go to Brief Summary: Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya disease and stroke patients Condition or disease Intervention/treatment Phase Cerebrovascular Accident Moyamoya Disease Drug: Xenon contrast agent Device: Magnetic Resonance Imaging Not Applicable Detailed Description: In the early hours following (...) and non-pregnant women, at least 21 years of age. Patients admitted to the inpatient Stanford Stroke Service for stroke-like symptoms, less than 24 hours from last time seen normal. Ability to comply with all studies. Clinical Patient Acetazolamide MRI Inclusion Criteria: Men and non-pregnant women, at least 21 years of age. Patients admitted to the inpatient Stanford Stroke Service or Neurosurgical -Service for symptoms compatible with cerebrovascular disease. Ability to comply with all studies

2011 Clinical Trials

85. Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

containing ≥3 mm of tissue with carcinoma or equivalent tumor specimen as confirmed by pathologist A primary tumor Gleason score ≥ 7 Adequate primary biopsy tissue or equivalent tumor specimen as confirmed by pathologist available for protocol required analysis (i.e. bladder or TURP specimen) Planning to have or have had a radical prostatectomy (RP) at MSKCC Candidates may have a history of deep vein thrombosis, pulmonary embolism, and/or cerebrovascular accident, or require concomitant systemic (...) Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2012 Clinical Trials

86. Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma

failure, as defined by the New York Heart Association (NYHA) Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg]. Cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (...) Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2012 Clinical Trials

87. Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype

illness including, significant ongoing or active infection, New York Heart Association (NYHA) Grade III or IV congestive heart failure, unstable angina or new onset angina or myocardial infarction within the past 6 months, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy, thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within past 3 months. Serious medical or psychiatric illness/social situations that in the opinion (...) Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2012 Clinical Trials

88. Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients

cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months. Any of the following within the 12 months prior to study drug administration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism. Gastrointestinal abnormalities Contacts and Locations (...) Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Adjuvant Axitinib

2012 Clinical Trials

89. Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug. Participation in any study of an investigational agent (drug, biologic, device) within 30 days, unless during nontreatment phase. Prior treatment with a JAK 2 Inhibitor. Treatment with aspirin in doses >150 mg/day (...) Known human immunodeficiency virus or acquired immunodeficiency syndrome-related illness. Pregnant or lactating female. Once the lactating female stop and participate in the study, she cannot re-start feeding the baby. Women of childbearing potential, unless using effective contraception while on study drug. Otherwise patients must be post-menopausal (at least 1 years from last menstruation without other medical reason), or surgically sterile. Known active (acute or chronic) Hepatitis A, B, or C

2012 Clinical Trials

90. A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced Ultrasound (US) in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy

: systolic blood pressure (BP) >150 mm Hg and/or diastolic BP >90 mm Hg despite optimal medical management not controllable by medication to achieve BP <15/90) Is in an intensive care setting Has an unstable neurological disease (e.g recent stroke or TIA symptoms (<3 months)) cerebrovascular accident (including transient ischemic attacks (TIAs) within the 3 months before signing of informed consent Undergone an invasive procedure on kidney lesion (e.g. tissue biopsy, surgery, nonsurgical cytoreductive (...) A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced Ultrasound (US) in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2012 Clinical Trials

91. Continual Long-Term Physiotherapy After Stroke

, and participation in formal physiotherapy sessions may also affect the speed and quality of recovery. 3 Personalized physiotherapy helps minimize disability after a stroke. Since some people present with persisting disabilities, long-term (i.e., chronic or maintenance) physiotherapy may reduce the risk of progressive worsening, as recovery may continue well beyond 3 months after stroke. 5 Continual assessment and tracking of functional status over time is important when determining the need for continual (...) -specific, time-limited, goal-oriented physiotherapy services that may be provided to a specific person. These clinic-based services provide care under the EOC model to a limited number of people each year. Each clinic manages its resources and allocations, but there are specified eligibility criteria. Services funded under this program are not intended to maintain existing function but rather to address recent acute episodes resulting from a previous illness, injury, accident, surgery, or flare-up

2020 Health Quality Ontario

92. Mechanical thrombectomy devices for acute ischaemic stroke

within 6 hours. Current NHS pathway People with suspected acute stroke should be admitted to the nearest accident and emergency department with a hyperacute stroke unit or a specialist stroke unit for immediate brain imaging (usually within 1 hour). If imaging confirms a diagnosis of acute ischaemic stroke then urgent thrombolysis should be given to try to restore blood flow in the brain. Other forms of pharmacological therapy are often used, whether or not thrombolysis has been attempted (...) and equality of opportunity between men and women, eliminate unlawful discrimination on grounds of race, disability, age, sex, gender reassignment, marriage and civil partnership, pregnancy and maternity (including women post-delivery), sexual orientation, and religion or belief (these are protected characteristics under the Equality Act 2010). Mechanical thrombectomy devices for acute ischaemic stroke (MIB153) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

2018 National Institute for Health and Clinical Excellence - Advice

93. The use of statins in the primary prevention of cardiovascular disease: an online tool for shared-decision making

% of new statins users do not take this treatment correctly or terminate their therapy early. 1 By lowering the blood cholesterol levels, statins are supposed to decrease the risk of myocardial infarction and cerebrovascular accidents in primary prevention, that is, in persons who have not yet suffered a CVD. But in terms of actual benefit for health, their adverse effects should also be taken into account. The adverse effects are supposedly infrequent, but poorly KCE Report 324 Use of statins: online (...) 51 Figure 9 – Printed/saved results 52 Figure 10 – Information for the patients - menu (French and Dutch) 54 Figure 11 – Content of the information for the patients (French and Dutch) 55 Figure 12 – The 'about this site' page (French and Dutch) 58 Figure 13 – Linear correlations between the chart and the tool risk value of SCORE in women with HDL cholesterol=0.8mmol/l, in non-smoker (left panel) and smoker (right panel). 64 Figure 14 – Linear correlations between the chart and the tool risk value

2020 Belgian Health Care Knowledge Centre

94. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD Full Text available with Trip Pro

is not recommended for CV risk stratification. 5.1 Diabetes, pre-diabetes, and cardiovascular risk The Emerging Risk Factor Collaboration, a meta-analysis of 102 prospective studies, showed that DM in general (data on DM type were unavailable) confers a two-fold excess risk of vascular outcomes (coronary heart disease, ischaemic stroke, and vascular deaths), independent of other risk factors ( Figure ). The excess relative risk of vascular events with DM was greater in women and at younger ages. Both relative (...) , and renal complications were the major determinants of outcome. , Although T2DM is far more common than T1DM, these results confirm the loss of years of life in both populations, which is particularly severe in the young in general and perhaps in young-onset female individuals with T1DM, emphasizing the need for intensive risk-factor management in these groups. In this document, we will be referring mostly to DM; this can be taken as relating to both types of DM unless otherwise specified. Figure 1

2019 European Society of Cardiology

95. Patent foramen ovale (PFO) closure in patients with cryptogenic ischaemic stroke

embolism is the most likely explanation for the stroke. In exploring patient preferences, the potential benefits and risks of the PFO closure procedure compared with medical therapies alone should be highlighted, including the risk of developing persistent atrial fibrillation or flutter. PFO closure plus antiplatelet therapy is unlikely to be cost-effective in the short-term (up to 10 years) but becomes cost effective over the lifetime of the patient, with an incremental cost effectiveness ratio (ICER (...) therapy. Patients who have a cryptogenic ischaemic stroke are typically younger (60 or under) and have fewer comorbidities compared with patients diagnosed with other stroke sub-types. Long-term medical therapy and risk of ischaemic stroke recurrence can place a significant burden on patients and the health service. Studies suggest there is a potential association between cryptogenic ischaemic stroke and the presence of a PFO. Closing this PFO may provide a way of reducing lifetime risk of ischaemic

2020 SHTG Advice Statements

96. Perioperative

and stroke. In patients with three or more RCRI risk factors (e.g., diabetes mellitus, HF, CAD, renal insufficiency, cerebrovascular accident), it may be reasonable to begin beta blockers before surgery. (ACC/AHA 2014 guideline recommendation) In patients with a compelling long-term indication for betablocker therapy but no other RCRI risk factors, initiating beta blockers in the perioperative setting as an approach to reduce perioperative risk is of uncertain benefit. (ACC/AHA 2014 guideline (...) Not applicable 1. Clinicians should use a validated standardized screening tool to screen patients for suspected sleep apnea (risk factors or patient reporting problems) or sleep apnea symptoms, and communicate to the surgical team. Major risk factors for sleep apnea include obesity, increased neck size (> 37 cm in men, >35 cm in women), craniofacial abnormalities, older age and male sex. 2. Clinicians should remind patients who have been formally diagnosed with obstructive sleep apnea and have an oral

2020 Institute for Clinical Systems Improvement

97. Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease

are effective for glycemic control, to date, only GLP-1 agonists and SGLT-2 inhibitors have trial evidence to demonstrate their ability to reduce major cardiovascular disease (CVD) outcomes such as myocardial infarction (MI), cerebrovascular accidents (CVA), and CVD mortality. Recent comprehensive and well conducted meta-analyses have estimated the effectiveness and safety of individual classes of medications in comparison to placebo and other classes of medications. 4, 5 Because the FDA began requiring (...) , but not urinary, infections. In CANVAS (evaluating canagliflozin), the only trial allowing for estimation of absolute excess cases per 1000 person-years, the excess number of genital infections in men is 24.1 cases per 1000 person-years and in women is 51.3 cases per 1000 person-years in persons randomized to taking SGLT-2 inhibitors versus placebo controls (Table 12). Observational studies support these findings. One systematic review found that regulatory data, but not published trials, demonstrated a risk

2019 Kaiser Permanente National Guideline Program

98. Venous Thromboembolism (VTE)

, May 2014 Table 1. Glossary of Abbreviations aPTT Activated Partial Thromboplastin Time APS Antiphospholipid antibody syndrome ABGs Arterial Blood Gases BNP B-type natriuretic peptide CVA Cerebrovascular accident CTEPH Chronic thromboembolic pulmonary hypertension CTA Computed tomography angiography CTV Computed tomographic venography COCs Estrogen-containing combined oral contraceptives DVT Deep venous thrombosis GSV Great saphenous vein HIT Heparin-induced thrombocytopenia HRT Hormone replacement (...) ]. Treatment Heparin Low molecular weight heparin (LMWH). LMWH is preferred for initial treatment over unfractionated heparin (UFH) or fondaparinux due to better safety and outcomes [IA]. Outpatient use of LMWH for DVT. LMWH is appropriate for most patients with DVT to use at home [IIA]. Some require initial brief hospital admission and stabilization. Clinically stable patients not at elevated risk due to comorbidities can be managed entirely as outpatients using LMWH. Unfractionated heparin. UFH

2020 University of Michigan Health System

99. Istradefylline (Nourianz) - Parkinson's disease

that would preclude Regulatory Action approval. If efficacy is demonstrated and the benefits of istradefylline outweight the risks, then I recommend that approval include appropriate labeling language addressing any adverse reactions of concerns. Recommended Adults Indication(s)/Population(s) (if applicable) CDER Clinical Review Template Version date: September 6, 2017 for all NDAs and BLAs Reference ID: 4482736 Reference ID: 4484018 1 Clinical Review Natalie Branagan, MD NDA 022075 Nourianz (...) /istradefylline Table of Contents Glossary 9 1. Executive Summary 11 1.1. Product Introduction 11 1.2. Conclusions on the Substantial Evidence of Effectiveness 11 1.3. Benefit-Risk Assessment 11 1.4. Patient Experience Data 15 2. Therapeutic Context 15 2.1. Analysis of Condition 15 2.2. Analysis of Current Treatment Options 15 3. Regulatory Background 15 3.1. U.S. Regulatory Actions and Marketing History 15 3.2. Summary of Presubmission/Submission Regulatory Activity 15 3.3. Foreign Regulatory Actions

2019 FDA - Drug Approval Package

100. Crizanlizumab, Voxelotor, and L-Glutamine for Sickle Cell Disease: Effectiveness and Value

crises, or even to the better known acute and chronic organ effects. Pain crises are, of course, horrible to experience, and their accumulated impact over many years has effects on physical and mental health as well as the potential risks associated with opioid treatment 12 In addition, the range of acute adverse effects of the condition includes almost every organ system, with strokes, ACS, and other life-threatening events a constant threat. These acute effects contribute to long-term risks (...) - Crizanlizumab, Voxelotor, and L-Glutamine for SCD Return to Table of Contents who was not a trained clinician, told us about needing to adjust a patient’s oxygen level while in the hospital out of fear that inadequate attention from the attending providers would prove fatal to the patient. While the management of pediatric patients with SCD has improved dramatically in recent years, the transition from pediatric to adult care presents a major risk for many patients. There is a significant shortage of adult

2020 California Technology Assessment Forum

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>